Efficacy and Tolerability of MK0533 in Patients With Type 2 Diabetes (0533-005)

• Status: Terminated
• Trial end date: 2007-08-01
• Target enrollment: 0
• Participant gender: All

Summary

A study to evaluate the effectiveness and tolerability of MK0533 and pioglitazone in patients with type 2 diabetes mellitus.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.
• Treatments: Pioglitazone

Criteria

Inclusion Criteria:

• Patients between the ages of 18 to 70 years with Type 2 diabetes who have not been able to adequately control their blood glucose levels

• Note: Only patients who have not been taking any antihyperglycemic medicine for 3 months will be screened

Exclusion Criteria:

• Patients taking any medicines that affect body fluid level such as a diuretic or water pill

• Patients taking niacin or other certain medications

• Patients with any of the following conditions: liver or kidney disease, poorly controlled high blood pressure, heart disease or certain blood disorders

• Patients with abnormal laboratory results from a blood test that will be given before each patient starts the study